David Thomas

36PUBLICATIONS
292CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Cancer diagnosisMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Jun 16, 2026
Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.

|Apr 24, 2026
Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial.

|Apr 23, 2026
Impact of Spiritual Wellbeing in Advanced Cancer Patients Receiving Genomic Test Results.

|Mar 27, 2026
Challenging interpretation of low-level PTCH1 mosaicism in patients with clinically diagnosed Gorlin syndrome: a case series and review of the literature.

Tanya M Dwarte, Rozanna Alli, Shweta Srinivasa

|Feb 13, 2026
Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation.

Benjamin Koh, Subotheni Thavaneswaran, Frank Lin

|Jan 09, 2026
TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors.

David M Thomas, Jeong Eun Kim, Fabrice Barlesi

Pageof 6

Frequent Collaborators

16 joint publications

Mandy L Ballinger

10 joint publications

Megan C Best

10 joint publications

Phyllis Butow

9 joint publications

Christine Napier